Drugs / PICOPREP
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT02239692 | Nov 2014 → Jun 2015 | — | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01356407 | Jan → May 2011 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01073930 | May → Oct 2010 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01073943 | May → Oct 2010 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04474002 | Dec 2020 → Dec 2022 | — | Queen Elizabeth Hospital, Hong Kong | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05436054 Comparator | Oct 2022 → Dec 2025 overdue | colonic disorder | Aalborg University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PicoPrep | “PicoPrep™” NCT01073930 ↗ |
| Modality | Small molecule | “Active substances: An envelope Picoprep® contains 10 mg sodium picosulfate, 3,5 g magnesium oxide, and 12 g citric acid.” NCT05436054 ↗ |
| Route | Oral | “PicoPrep: 2-sachets for oral solution in two divided doses” NCT01073930 ↗ |